PHASE III TRIAL COMPARING, NEOADJUVANT CHEMOTHERAPY FOLLOWED BY STANDARD RADIOTHERAPY VERSUS THE SAME NEOADJUVANT CHEMOTHERAPY FOLLOWED BY STANDARD RADIOTHERAPY ASSOCIATED WITH DAILY HYDROXYUREA IN THE TREATMENT OF LOCALLY ADVANCED UNDIFFERENTIATED CARCINOMA NASOPHARYNGEAL TYPE.
Phase 3
- Conditions
- LOCALLY ADVANCED UNDIFFERENTIATED CARCINOMA NASOPHARYNGEAL TYPE UCNT
- First Posted Date
- 2005-09-16
- Last Posted Date
- 2005-09-16
- Lead Sponsor
- Gustave Roussy, Cancer Campus, Grand Paris
- Target Recruit Count
- 520
- Registration Number
- NCT00180973
- Locations
- 🇫🇷
Institut Gustave Roussy, Villejuif, France
Unmodified Versus Leuko-Reduced Allogeneic Red Blood Cells Transfusion in Cancer Patients
Phase 3
Completed
- Conditions
- CancerSurgery
- First Posted Date
- 2005-09-16
- Last Posted Date
- 2005-09-16
- Lead Sponsor
- Gustave Roussy, Cancer Campus, Grand Paris
- Target Recruit Count
- 150
- Registration Number
- NCT00180869
- Locations
- 🇫🇷
Institut Gustave Roussy, Villejuif, France
Radiofrequency Ablation of Lung Tumors
Phase 2
Completed
- Conditions
- Lung CancerMetastasis
- First Posted Date
- 2005-09-16
- Last Posted Date
- 2005-09-16
- Lead Sponsor
- Gustave Roussy, Cancer Campus, Grand Paris
- Target Recruit Count
- 60
- Registration Number
- NCT00180856
- Locations
- 🇫🇷
Institut Gustave Roussy, Villejuif, France
🇫🇷Institut Bergonié, Bordeaux, France
Clinical Utility of the Alaris MidLatencyAuditoryEvoked Potentials Monitor to Titrate the Anesthetic-Hypnotic Component of Anesthesia
Phase 3
Suspended
- Conditions
- Scheduled General Anesthesia
- First Posted Date
- 2005-09-16
- Last Posted Date
- 2005-09-16
- Lead Sponsor
- Gustave Roussy, Cancer Campus, Grand Paris
- Target Recruit Count
- 128
- Registration Number
- NCT00181051
- Locations
- 🇫🇷
Institut Gustave-Roussy, Villejuif, France
Comparison of High-Dose Methotrexate (HDM) Plus Doxorubicin to HDM Plus Etoposide-Ifosfamide in Osteosarcoma Children
Phase 3
Completed
- Conditions
- OsteosarcomaLocalised High Grade Osteosarcoma of the Limbs
- First Posted Date
- 2005-09-16
- Last Posted Date
- 2005-09-16
- Lead Sponsor
- Gustave Roussy, Cancer Campus, Grand Paris
- Target Recruit Count
- 226
- Registration Number
- NCT00180908
- Locations
- 🇫🇷
Institut Gustave-Roussy, Villejuif, France
Randomised Study to Compare the Effect of r-Hu-EPO Administration With Transfusion of Red Blood Cell Concentrates and Also With the Administration of Polyvitamins in Anemic and Tired Patients Presenting a Bad Prognostic in Middle Course
Phase 3
Terminated
- Conditions
- - Medico-Economic Aspects (Evaluation of Medical Costs Related to the Three Strategies and Evaluation of Cost/Efficacy)
- First Posted Date
- 2005-09-16
- Last Posted Date
- 2006-09-11
- Lead Sponsor
- Gustave Roussy, Cancer Campus, Grand Paris
- Target Recruit Count
- 420
- Registration Number
- NCT00180999
- Locations
- 🇫🇷
Institut Gustave-Roussy, Villejuif, France
Treatment of Mature B-cell Lymphoma/Leukaemia
Phase 3
Completed
- Conditions
- B-Cell Lymphoma
- Interventions
- Drug: LMB BDrug: without COPADM3Drug: LMB CDrug: mini CYVE, without 3 maintenance courses
- First Posted Date
- 2005-09-13
- Last Posted Date
- 2012-03-28
- Lead Sponsor
- Gustave Roussy, Cancer Campus, Grand Paris
- Target Recruit Count
- 848
- Registration Number
- NCT00162656
- Locations
- 🇬🇧
Sheffield Children's Hospital, Sheffield, United Kingdom
🇫🇷Institut Gustave Roussy, Villejuif, France
🇺🇸Morgan Stanley Childrens Hospital of New York Presbyterian, New York, New York, United States
The Addition of Polychemotherapy to Adjuvant Radiotherapy in the Treatment of Non-Metastatic Uterine Sarcomas
Phase 3
- Conditions
- Uterine Sarcoma
- First Posted Date
- 2005-09-13
- Last Posted Date
- 2007-08-10
- Lead Sponsor
- Gustave Roussy, Cancer Campus, Grand Paris
- Target Recruit Count
- 270
- Registration Number
- NCT00162721
- Locations
- 🇫🇷
Institut Gustave Roussy, Villejuif, France
Bevacizumab in Advanced Hepatocellular Carcinoma
Phase 2
- Conditions
- Hepatocellular Carcinoma
- First Posted Date
- 2005-09-13
- Last Posted Date
- 2006-09-08
- Lead Sponsor
- Gustave Roussy, Cancer Campus, Grand Paris
- Target Recruit Count
- 50
- Registration Number
- NCT00162669
- Locations
- 🇫🇷
Institut Gustave Roussy, Villejuif, France
Very Intense Radiotherapy-Chemotherapy Regimen in Advanced HNSCC
Phase 2
Completed
- Conditions
- Oropharynx CancerOral CancerHypopharynx CancerLarynx Cancer
- First Posted Date
- 2005-09-13
- Last Posted Date
- 2005-09-13
- Lead Sponsor
- Gustave Roussy, Cancer Campus, Grand Paris
- Target Recruit Count
- 120
- Registration Number
- NCT00162708
- Locations
- 🇫🇷
Centre Alexis Vautrin, Nancy, France
🇫🇷Centre Jean Perrin, Clermont-Ferrand, France
🇫🇷Institut Gustave Roussy, Villejuif, France
© Copyright 2025. All Rights Reserved by MedPath